Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer clinical trial (NCT01896271). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the combination of high-dose IL-2 and SABR compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer clinical trial (NCT01896271). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of this treatment combination?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer clinical trial (NCT01896271). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic if I participate in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer clinical trial (NCT01896271). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the treatment process?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer clinical trial (NCT01896271). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial impact my overall treatment plan and goals?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer clinical trial (NCT01896271). Contact the study team or your healthcare provider for specific answers.

What this study is about